Naltrexone Treatment for Prolonged Grief Disorder (PGD)

Phase 4 Terminated 9 enrolled Weill Medical College of Cornell University

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a study to see how effective oral naltrexone is as treatment for prolonged grief disorder (PGD). Participants will take their assigned medication for 8 weeks, with monthly visits to assess symptom severity, social connectedness, and adverse reactions.

Timeline

Start: 2021-01-05
Primary completion: 2023-10-16
Completion: 2023-10-16

Publications

Background Kakarala SE, Roberts KE, Rogers M, Coats T, Falzarano F, Gang J, Chilov M, Avery J, Maciejewski PK, Lichtenthal WG, Prigerson HG. The neurobiological reward system in Prolonged Grief Disorder (PGD): A systematic review. Psychiatry Res Neuroimaging. 2020 Sep 30;303:111135. doi: 10.1016/j.pscychresns.2020.111135. Epub 2020 Jul 3.
Gang J, Kocsis J, Avery J, Maciejewski PK, Prigerson HG. Naltrexone treatment for prolonged grief disorder: study protocol for a randomized, triple-blinded, placebo-controlled trial. Trials. 2021 Feb 1;22(1):110. doi: 10.1186/s13063-021-05044-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Naltrexone	Small molecule	50 mg	Oral

Indications

No indication recorded.